1984 - 1988  B.S, Jilin University

1988 - 1991  M.S, Jilin University

1994 - 1997  Ph.D, China Institute of Atomic Energy

1998 - 2000  Postdoctoral Fellow, Oak Ridge National Laboratory; Washington University School of Medicine

1991 - 2008  Assistant Professor, Associate Professor, and Professor, China Institute of Atomic Energy

2001 -           Professor, Peking University Health Science Center

2013 -           Professor and Principal Investigator (Guest), Institute of Biophysics, Chinese Academy of Sciences

2011  National Outstanding Youth, NSFC

2008  Berson-Yalow Award, Society of Nuclear Medicine, USA

Molecular imaging, a rapid growing research field in the last decade, provides a powerful tool for the noninvasive characterization and quantification of biological processes in living subjects at the cellular and molecular levels. Central to molecular imaging is the development of imaging probes. Our research interests focus on the design and development of a series of novel molecular probes targeted to the key biomarkers during disease progress. By optimizing in preclinical animal models and clinical trials, these novel probes are expected to play pivotal roles in early disease detection and staging, as well as real-time response monitoring towards personalized therapy.

1. Ma X, Liang X, Yao M, Gao Y, Luo Q, Li X, Yu Y, Sun Y, Cheng MHY, Chen J, Zheng G*, Shi J*, Wang F*. Myoglobin-loaded gadolinium nanotexaphyrins for oxygen synergy and imaging-guided radiosensitization therapy. Nat Commun. 2023; 14(1):6187.

2. Gao Y^#, Luo Q^#, Sun Z, Gao H, Yu Y, Sun Y, Ma X, Han C, Shi J*, Wang F*. Implication of ^99mTc-sum IL-2 SPECT/CT in immunotherapy by imaging of tumor-infiltrating T cells. J Immunother Cancer. 2023; 11(3):e005925.

3. Shi J^#, Du S^#, Wang R^#, Gao H, Luo Q, Hou G, Zhou Y*, Zhu Z*, Wang F*. Molecular imaging of HER2 expression in breast cancer patients using a novel peptide-based tracer ^99mTc-HP-Ark2: a pilot study. J Transl Med. 2023; 21(1):19.

4. Liu T, Wu Y, Shi L, Li L, Hu B, Wang Y, Gao H, Yu X, Zhang X, Zhao H, Wan Y, Jia B*, Wang F*. Preclinical evaluation of [99mTc]Tc-labeled anti-EpCAM nanobody for EpCAM receptor expression imaging by immuno-SPECT/CT. Eur J Nucl Med Mol Imaging. 2022; 49(6):1810-1821.

5. Luo Q^#, Zhang Y^#, Wang Z^#, Sun Y, Shi L, Yu Y, Shi J*, Hu Z*, Wang F*. A novel peptide-based probe ^99mTc-PEG6-RD-PDP2 for the molecular imaging of tumor PD-L2 expression. Chinese Chem Lett. 2022; 33(7):3497-3501.

6. Zhao H^#, Gao H^#, Luo C, Yang G, Zhao X, Gao S, M Q, Jia B, Shi J*, Wang F*. An Integrin-αvβ6/α5β1-Bitargeted Probe for the SPECT Imaging of Pancreatic Adenocarcinoma in Preclinical and Primary Clinical Studies. Bioconjugate Chem. 2021; 32(7):1298-1305.

7. Zhang C, Gao Y, Du C, Markowitz GJ, Fu J, Zhang Z, Liu C, Qin W, Wang H, Wang F*, Yang P*. Hepatitis B-induced IL-8 Promotes Hepatocellular Carcinoma Venous Metastasis and Intrahepatic Treg Accumulation. Cancer Res. 2021; 81(9):2386-2398.

8. Ma X, Yao M, Shi J, Li X, Gao Y, Luo Q, Hou R, Liang X*, Wang F*. High Intensity Focused Ultrasound-Responsive and Ultra-stable Cerasomal Perfluorocarbon Nanodroplets for Alleviating Tumor Multidrug Resistance and Epithelial-Mesenchymal Transition, ACS Nano. 2020; 14(11):15904-15918.

9. Gao H^#, Wu Y^#, Shi J^#, Zhang X, Liu T, Hu B, Jia B, Wan Y, Liu Z, Wang F*. Nuclear Imaging-Guided PD-L1 Blockade Therapy Increases Effectiveness of Cancer Immunotherapy. J Immunother Cancer. 2020; 8(2):e001156.

10. Gao,S Jia B, Feng G, Dong C, Du H, Bai L, Zhong Q, Ma Q*, Zeng M*, Wang F*. First-in-human pilot study of an integrin α6-targeted radiotracer for SPECT imaging of breast cancer. Signal Transduction and Targeted Therapy. 2020; 5(1):147.

11. Wu Y, Li L, Wang Z, Shi J, Hu Z, Gao S, Miao W, Ma Q, Dong C*, Wang F*. Imaging and Monitoring HER2 Expression in Breast Cancer During Trastuzumab Therapy with a Peptide Probe ^99mTc-HYNIC-H10F. Eur J Nucl Med Mol Imaging. 2020; 47(11):2613-2623.

12. Yao M, Ma X, Zhang X, Shi L, Liu T, Liang X, Zhao H, Li X, Li L, Gao H, Jia B*, Wang F*. Lectin-mediated pH-sensitive Doxorubicin Prodrug for Pre-targeted Chemotherapy of Colorectal Cancer with Enhanced Efficacy and Reduced Side Effects. Theranostics. 2019; 9(3):747-760.

13. Ma X, Li X, Shi J, Yao M, Zhang X, Hou R, Shao N, Luo Q, Gao Y, Du S, Liang X*, Wang F*. Host-Guest Polypyrrole Nanocomplex for Three-Stimuli-Responsive Drug Delivery and Imaging-Guided Chemo-Photothermal Synergetic Therapy of Refractory Thyroid Cancer. Adv Healthc Mater. 2019; 8(17):e1900661.

14. Liang X*, Fang L, Li X, Zhang X, Wang F*. Activatable near infrared dye conjugated hyaluronic acid based nanoparticles as a targeted theranostic agent for enhanced fluorescence/CT/photoacoustic imaging guided photothermal therapy. Biomaterials. 2017; 132:72-84.

15. Li L^#, Wu Y^#, Wang Z, Jia B, Hu Z, Dong C, Wang F*. SPECT/CT Imaging of the Novel HER2-Targeted Peptide Probe ^99mTc-HYNIC-H6F in Breast Cancer Mouse Models. J Nucl Med. 2017; 58(5):821-826.

16. Yu X, Wu Y, Liu H, Gao L, Sun X, Zhang C, Shi J, Zhao H, Jia B, Liu Z, Wang F*. Small-Animal SPECT/CT of the Progression and Recovery of Rat Liver Fibrosis by Using an Integrin alphavbeta3-targeting Radiotracer. Radiology. 2016; 279(2):502-512.

17. Liu Z*, Liu H, Ma T, Sun X, Shi J, Jia B, Sun Y, Zhan J, Zhang H, Zhu Z, Wang F*. Integrin α_vβ₆-targeted SPECT imaging for pancreatic cancer detection. J Nucl Med. 2014; 55(6):989-994.

18. Liu Z*, Sun X, Liu H, Ma T, Shi J, Jia B, Zhao H, Wang F*. Early Assessment of Tumor Response to Gefitinib Treatment by Noninvasive Optical Imaging of Tumor Vascular Endothelial Growth Factor Expression in Animal Models. J Nucl Med. 2014; 55(5):818-823.

19. Zhu Z, Weibing Miao W, Li Q, Dai H, Ma Q, Wang F, Yang A, Jia B, Jing X, Sha L, Shi J, Liu Z, Zhao Z, Wang F*, Li F*. ^99mTc-3PRGD2 for Integrin Receptor Imaging of Lung Cancer: a Multi-Center Study. J Nucl Med. 2012; 53(5):716-722.

Clinical Trial Approval

China Food and Drug Administration, a class 1 new drug clinical trial approval (drug name: ^99mTc-3PRGD₂ injection), approval number: 2018L02484. Currently in clinical phase III trials.

Patents

25 Patents: L200810239036.X; ZL200910077039.2; ZL201310304250.X; ZL2014100840659; ZL201410084837.9; L201611095315.4; ZL201611095338.5; ZL2017103346344; ZL2017103341374; L201710713055.0; L201711113966.6; ZL201811055196.9; ZL201910441556.7; L201910048535.9; L201910049263.4; L202010050493.5; ZL201610232756.8; L2019110099872; L202011166195.9; L202010373843.1; L201910778630.4; 202211594195.8; 202310898339.7; PCT/CN2023/073535; 202410731692.0

(From Fan Wang, September 13, 2024)